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Abstract
Background: Psychological treatments for dementia are widely used in the UK and internationally, but only rarely have 
they been standardised, adequately evaluated or systematically implemented. There is increasing recognition that 
psychosocial interventions may have similar levels of effectiveness to medication, and both can be used in 
combination. Cognitive Stimulation Therapy (CST) is a 7-week cognitive-based approach for dementia that has been 
shown to be beneficial for cognition and quality of life and is cost-effective, but there is less conclusive evidence for the 
effects of CST over an extended period.
Methods/Design: This multi-centre, pragmatic randomised controlled trial (RCT) to assess the effectiveness and cost-
effectiveness of Maintenance CST groups for dementia compares a intervention group who receive CST for 7 weeks 
followed by the Maintenance CST programme once a week for 24 weeks with the control group who receive CST for 7 
weeks, followed by treatment as usual for 24 weeks.
The primary outcome measures are quality of life of people with dementia assessed by the QoL-AD and cognition
assessed by the ADAS-Cog. Secondary outcomes include the person with dementia's mood, behaviour, activities of
daily living, ability to communicate and costs; as well as caregiver health-related quality of life. Using a 5%
significance level, comparison of 230 participants will yield 80% power to detect a standardised difference of 0.39 on
the ADAS-Cog between the groups. The trial includes a cost-effectiveness analysis from a public sector perspective.
Discussion: A pilot study of longer-term Maintenance CST, offering 16 weekly sessions of maintenance following the 
initial CST programme, previously found a significant improvement in cognitive function (MMSE) for those on the 
intervention group. The study identified the need for a large-scale, multi-centre RCT to define the potential longer-
term benefits of continuing the therapy. This study aims to provide definitive evidence of the potential efficacy of 
maintenance CST and establish how far the long-term benefits can be compared with antidementia drugs such as 
cholinesterase inhibitors.
Trial Registration: ISRCTN26286067
Background
Psychological treatments for dementia such as Reality
Orientation (RO) and Reminiscence have been in use for
nearly half a century, and are widely used in the UK and
internationally, but often have not been standardised,
adequately evaluated or systematically implemented. A
number of systematic reviews of psychosocial interven-
tions are now available [1-3], as well as a number of
Cochrane reviews of specific approaches [e.g. [4,5]]. The
Spector review of RO [5] was used to develop a seven-
week evidence-based Cognitive Stimulation Therapy
(CST) programme for people with dementia [6]. A total
of 201 people with dementia were recruited for this sin-
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dential homes in greater London. The CST group
improved significantly on the main outcome measures
(cognition and quality of life). CST compared favourably
with cholinesterase inhibitors for Alzheimer's disease in
terms of numbers needed to treat (NNT) [6] and the eco-
nomic analysis showed that CST was likely to be cost-
effective [7]. The recent UK guidelines on dementia [8]
recommend that all people with mild/moderate dementia
should be 'given the opportunity to participate in a struc-
tured group cognitive stimulation programme'.
The evidence for the long-term effects of CST is less
conclusive. Feedback from the CST training and previous
studies [6] suggested that service users preferred a lon-
ger-term programme after the seven-week CST interven-
tion. A number of studies have looked at the longer-term
effects of cognitive stimulation and related interventions.
A recent pilot study of longer-term CST (maintenance
CST) [9], offering 16 weekly sessions of maintenance, fol-
lowing the initial CST programme, found a significant
improvement in cognitive function (MMSE) for those
receiving ongoing Maintenance CST. This lasted nearly 6
months in comparison to a group of CST only and con-
trols (p = 0.012). The study identified the need for a large-
scale, multi-centre RCT to define the potential longer-
term benefits of MCST for dementia. A number of other
studies have looked at the longer-term effects of cognitive
stimulation and related interventions in combination
with cholinesterase inhibitors. Two recent RCTs found
that over 6 months, cognitive stimulation and cholinest-
erase inhibitors in combination, were more effective than
cholinesterase inhibitors alone [10,11]. There is a distinct
overlap between what is described as Reality Orientation
(RO) and Cognitive Stimulation. Both programmes often
describe similar features, whilst more emphasis is placed
on re-learning orientation information in RO, Cognitive
Stimulation focuses on implicit information processing.
Studies have suggested that with a RO intervention, the
cognitive benefits gained were lost after 10 weeks [12]
and one month [13] after stopping the programme. How-
ever, Wallis et al. [13] found that behavioural functioning
continued to improve 10 weeks after the RO programme
terminated. Other studies have suggested that longer pro-
grammes of RO may have longer-term effects [14,15].
Zanetti et al. [14], found, in a RCT, that the effect of RO
on cognitive performance appeared to counteract the
decline, observed in the control group, of 2.58 points on
the MMSE. Similarly Metitieri et al. [15] found that peo-
ple receiving long-term treatment declined in cognitive
function significantly later, and remained at home longer
than those receiving a shorter programme of RO. Both
studies concluded that providing a longer term RO inter-
vention was effective in slowing, at least temporarily, the
dementia process. A novel aspect of the Zanetti et al
study [14] was that they described an expected yearly
decrease in Mini-Mental-State-Examination score [16] of
1.8-4.2 points in people with dementia. Therefore, it
might be that pre-post comparisons in the studies which
had used longer interventions (20 and 21 weeks) would
have shown weaker results [17,18] as a result of the
expected yearly decrease.
It is unclear how far maintenance programmes of CST
might continue to benefit the participants. The studies
included in the recent CST Cochrane review [19] ranged
from using programmes of four weeks [20] to one year
[21]. However, no relationship between the duration of
the intervention and the outcome was shown. The trials
with the strongest results and higher weight in the meta-
nalyses [6,11] had 7 to 25 weeks of intervention respec-
tively. Stronger evidence of their effectiveness is needed
to support the long-term implementation of CST. It is
also necessary to examine whether the combination of
Maintenance CST with cholinesterase inhibitors for
Alzheimer's disease is cost-effective and brings extra
long-term benefits to cognition and quality of life of peo-
ple with dementia. This paper describes the study proto-
col for a pragmatic RCT of CST versus CST followed by a
24 week maintenance CST programme undertaken with
people experiencing mild to moderate dementia. This
research programme aims to provide essential evidence
to clarify the role of long-term CST interventions alone
and in combination with cholinesterase inhibitors and
the analyses of its cost-effectiveness.
Methods/Design
The design is a single-blind, multi-centre, randomized
controlled trial of Cognitive Stimulation Therapy (CST)
groups for dementia vs. Maintenance CST groups (extra
24 sessions once a week) (Figure 1). After completion of
the initial CST programme (twice weekly, 45-minute ses-
sions for 7 weeks), participants are randomly allocated
into treatment group (maintenance sessions once a week
for 24 weeks) or control group (treatment as usual for 24
weeks).
People with Alzheimers disease are offered cholinest-
erase inhibitors by their local clinical team provided that
they are willing and eligible (according to NICE guide-
lines [8]) for the medication. People currently on cholin-
esterase inhibitors will continue taking them. Participants
enter the study after giving signed informed consent in
accordance with the provisions of the Mental Capacity
Act 2005. Ethical approval was obtained through the
Multi-centre Research Ethics Committee (ref no. 08/
H0702/68). The clinical trial is registered - ISRCTN
26286067.
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Figure 1 Flow diagram of the trial; Trial and randomisation stages.
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Recruitment to this trial is currently taking place through
day centres, residential homes and Community Mental
Health Teams (CMHTs) in the participating study cen-
tres, with at least a minimum of 14 potential participants.
Half of the sample to be recruited from the community
(50%) and the other half of the sample (50%) from care
homes. Potential centres (day centres, CMHTs and resi-
dential homes) are screened for eligibility to determine
whether there are sufficient numbers of potential partici-
pants with dementia, using the inclusion criteria flow
chart. (Appendix 1). People with dementia meeting the
inclusion criteria are recruited into the two CST groups
that are running per centre (7 to 10 per group).
Randomisation
The randomisation process in this trial is undertaken in
two stages, randomisation 1 and randomisation 2. Figure
1 sets out the two-stage randomisation process. The allo-
cation ratio at randomisation 1 stage is 1:1; into either
group A or group B, with both groups receiving 7 weeks
of CST. The allocation ratio at randomisation 2 stage is
1:1; into either the control group or treatment group. The
sample is stratified to ensure that equal numbers of par-
ticipants taking cholinesterase inhibitors are randomised
into either the Maintenance CST or the control group.
The North Wales Organisation for Randomised Trials in
Health (NWORTH) is responsible for undertaking the
remote randomisation. NWORTH is accredited as a Clin-
ical Trials Unit by the UK Clinical Research Collabora-
tion (UKCRC) and funded as part of the Clinical
Research Collaboration Cymru, notably for HTA trials.
Blinding
Although participants cannot be blinded to their allo-
cated treatment, all follow-up data is gathered by inter-
viewers blind to groups. However our experience in the
CST trial, as shared by similar projects, is that partici-
pants may occasionally and inadvertently inform
researchers of the treatment they are receiving. We aim
to reduce this effect by giving explicit reminders to par-
ticipants before the assessment visit and by the use of
self-report measures wherever feasible. Assessors record
their impression of which arm of the trial each partici-
pant belongs to and their confidence in that prediction on
completion of the two follow up assessments. This
enables us to test whether inadvertent loss of blinding
leads to bias, and to adjust for any bias that may be
detected.
Intervention
CST is an intervention for people with mild to moderate
dementia, designed following extensive evaluation of the
available research and is an evidence-based treatment [6].
The programme consists of fourteen 45-minute sessions
which are run twice weekly. Each session incorporates
use of an 'RO board', displaying both personal and orien-
tation information, including the group name (as chosen
by participants). The guiding principles of CST involve
using new ideas, thoughts and associations; using orien-
tation (but sensitively and implicitly); a focus on opinions
rather than facts; using reminiscence as an aid to the
here-and-now; providing triggers to aid recall; creation of
continuity and consistency between sessions; focus on
implicit (rather than explicit) learning; stimulating lan-
guage; stimulating executive functioning and being per-
son-centred -(treating people as unique individuals with
their own personality and preferences). The CST pro-
gramme aims to create an environment where people
have fun, learn and where they strengthen their abilities
and relationships among the group members, thus main-
taining their social and cognitive skills at their optimum
ability.
The Maintenance Cognitive Stimulation Therapy
(CST) programme is an evidence-based maintenance
group therapy programme for people with dementia. It
comprises a programme of 24 sessions of maintenance
CST, based on the theoretical concepts of RO/Cognitive
Stimulation and grounded on the original CST pro-
gramme. The programme has been developed as part of
the Support at Home - Interventions to Enhance Life in
Dementia (SHIELD) research programme. The aim is to
create an evidence-based maintenance group therapy
programme for people with dementia based on the same
principles as the CST programme. A process of several
different methodological approaches has been used to
develop the maintenance CST programme. This includes
using the preliminary findings of a feasibility study into
maintenance CST [9] and data extracted from the
updated Cochrane review on cognitive stimulation for
people with dementia [19]. Consultation was achieved
with identified experts in the field, interested academics,
clinicians and service users, through holding a consensus
workshop and focus groups with people with dementia,
family caregivers and members of staff working directly
with people with dementia [22]. A summary of the CST
and maintenance CST programme can be found in Table
1.
Recruitment and training of facilitators
Each CST and maintenance CST group has two facilita-
tors, one from the research team and a co-facilitator who
is a member of staff from the recruited centre (e.g. care
home). The facilitators have at least one year of experi-
ence in dementia care. Main facilitators often have a
mental health nursing, occupational therapy or clinical
psychology background, experience in dementia care and
group facilitation skills. The use of two facilitators for
each group enables effective de-briefing and reflection to
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Table 1: CST and maintenance CST themes.
CST Programme
Session Number
Main Theme MCST Programme
Session Number
1 Physical games 8
2 Sound 7
3 My life 1 & 23
4 Food 3 & 17
5 Current affairs 2
6 Faces/Scenes 15
7 Associated Words, discussion 18
8 Being creative 4
9 Categorising objects 9
10 Orientation 19
11 Using Money (Clip Adverts II) 20
12 Number game 5
13 Word game 16 & 21
14 Team games, Quiz 6
N/A Useful tips 11 & 24
N/A Thinking cards 12
N/A Art Discussion 14
N/A Visual Clips Discussion 13
N/A Household Treasures 10 & 22
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one-day CST training developed by one of the CST pio-
neers (AS) as part of the dissemination strategy. The
training provides a detailed background and description
of CST, and uses learning methods including group
observation, role-playing and small group exercise.
Usual Care
The participants allocated to the control group receive
treatment as usual. This can vary between and within
centres and may change over time, but in principle, the
interventions offered to this group are also available to
those in the active treatment groups. Therefore, the trial
examines the additional effects of maintenance CST. Our
approach to costing the services and interventions
received will allow us to monitor whether the treatment-
as-usual group have been receiving similar therapeutic
interventions. Use of antidementia medication is
recorded as part of the costing information collected. It is
possible that participants in the treatment-as-usual group
are involved in some form of cognitive stimulation work
during the 24 weeks of the study period. However, it is
very unlikely that such a structured approach to CST is
offered in any of the centres. It is this systematic group-
based approach that is the focus of this evaluation.
Ethical arrangements
Risks and anticipated benefits for trial participants 
There appear to be no documented harmful side-effects
from participating in CST groups, and no serious adverse
reactions were apparent in the CST study. Benefits are
consistently reported by participants in the groups,
including enjoyment, feelings of validation and self-worth
[23]. The inclination of participants to continue meeting
following the sessions provides an indication of the value
placed on the benefits. Prospective participants are fully
informed of the potential risks and benefits of the project.
A reporting procedure is in place to ensure that serious
adverse events are reported to the Chief Investigator
(MO). Upon becoming aware of an adverse event involv-
ing a participant or carer, a senior clinical member of the
research team assesses its seriousness. A Serious Adverse
Event (SAE) is defined in the trial as an untoward occur-
rence experienced by either a participant or carer which:
• results in death;
• is life threatening;
• requires hospitalisation or prolongation of existing
hospitalisation;
• results in persistent or significant disability or inca-
pacity;
• is otherwise considered medically significant by the
investigator;
• falls within the scope of the Protection of Vulnerable
Adults (POVA) protocol which is in place to ensure that
suspected cases of abuse or neglect are followed-up in an
appropriate manner.
A reporting form is submitted to the CI who assesses
whether the SAE is related to the conduct of the trial and
is unexpected. SAEs that are judged to be related and
unexpected are reported to MREC and the trial DMEC.
Consent
Recruited participants are in the mild to moderate stages
of dementia, and would therefore generally be expected
to be competent to give informed consent for participa-
tion, provided that appropriate care is taken in explaining
the research and sufficient time allowed for them to reach
a decision. Wherever possible a family member or other
supporter is included. It is made clear to participants and
family care-givers that no disadvantage will occur if they
choose not to participate. In seeking consent, we follow
current guidance from the British Psychological Society
on evaluation of capacity. In this context, consent has to
be regarded as a continuing process rather than a one-off
decision, and willingness to continue participating will be
continually checked through discussion with participants
during the assessments. Where the participant's level of
impairment increases, so that they are no longer able to
provide informed consent, the provisions of the Mental
Capacity Act 2005 [24] will be followed. The initial giving
of informed consent can provide an indication of the per-
son's preference for participation in the research, and the
family care-giver's viewpoint can also be sought. If the
person with dementia shows discomfort at any point with
the assessments they can be discontinued.
Outcome measures
Primary and secondary measures are completed at base-
line (T0), after the seven weeks of the CST programme
(first follow up, T1), three months after beginning of the
maintenance groups (second follow-up T2) and six
months after the beginning of the maintenance groups
(third follow up and primary end-point T3).
Primary outcome measures
a) Cognition is measured using the ADAS-Cog [25]. The
ADAS-Cog consists of 11 tasks measuring the distur-
bances of memory, language, praxis, attention and other
cognitive abilities which are often referred to as the core
symptoms of AD.
b) Quality of life is measured using the Quality of Life--
Alzheimer's disease Scale [26]. The QOL-AD covers 13
domains of quality of life. It has good internal consis-
tency, validity and reliability and its use is recommended
by the European consensus on outcome measures for
psychosocial interventions in dementia [27].
Secondary Outcomes
a) Cognition using the Mini-Mental State Examination
(MMSE), [16]. The MMSE is a brief, widely used test of
cognitive function, with good reliability and validity.
b) Communication is assessed using the Holden Com-
munication Scale [28]. This scale is completed by staff or
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and communication variables.
c) Depression is assessed using the Cornell Scale for
Depression in Dementia [29]. This scale rates depression
in five broad categories using information from inter-
views with staff and participants. Good reliability and
validity have been demonstrated.
d) Anxiety is assessed using the Rating Anxiety in
Dementia scale [30] (RAID). This rates anxiety in four
main categories and uses interviews with staff and partic-
ipants. It has good validity and reliability.
e) Behaviour is assessed using the Neuropsychiatric
Inventory (NPI) [31]. The NPI assess 10 behavioural dis-
turbances occurring in dementia patients. Studies report
that it has good validity and reliability.
f ) Activities of daily living assessed using the
Alzheimer's Disease Co-operative Study - Activities of
Daily Living Inventory (ADCS-ADL) [32]. The ADCS-
ADL is a structured questionnaire originally created to
assess functional capacity over the range of dementia
severity. The sensitivity and reliability have been establish
[32].
g) Family Caregiver health is assessed using the Short
Form-12 Health Survey (SF-12) [33]. This scale measures
generic health concepts relevant across age, disease, and
treatment groups. The SF-12 includes 8 concepts com-
monly represented in health surveys. It is a self adminis-
trative measure that provides a comprehensive,
psychometrically sound, and efficient way to measure
health from the patient's point of view by scoring stan-
dardized responses to standard questions. This measure
is only used when a family caregiver is available from the
community sample participants.
h) Costs are assessed using the validated Client Services
Receipt Inventory (CSRI) [34], adapted for this study.
Used extensively in studies of mental health and demen-
tia [7], the CSRI gathers comprehensive data on accom-
modation, medication and services received. In this trial
the data will cover the previous three months (at baseline
and after treatment) or at three and six months follow-up.
Unit costs are then attached to services and support
received, based on nationally relevant estimates of long-
run marginal opportunity costs. Two quality of life mea-
sures are also included for cost utility analyses. The EQ-
5D [35] is a standardised instrument for use as a measure
of health-related quality of life. It contains a 3-level cod-
ing system for 5 dimensions. The instrument includes a
global rating of current health using a visual analog scale.
The DEMQOL [36] uses self-rated reports of QoL
administered by a trained interviewer; there is also a sep-
arate scale for family caregiver or members of staff
reports, the DEMQOL-proxy. It includes 5 domains of
quality of life. The DEMQOL has high internal consis-
tency and acceptable inter-rater reliability and indicates
concurrent validity through moderate associations with
the QOL-AD and DEMQOL [36].
Sample Size
The primary outcome measures are cognition (ADAS-
Cog) and quality of life (QoL-AD) at 24 weeks follow up.
In the pilot CST trial [6] which recruited people with
mild/moderate dementia (MMSE 10-24), community and
institutional participants had a similar level of cognitive
impairment (mean MMSE 14.5 and 14.1). The RO review
[5] found a moderate effect size of 0.58 between the RO
and control groups though the studies had some differ-
ences in methodology, outcome measures, and length of
treatment/follow up. The MCST pilot study found a large
effect size of 1.0 compared with CST alone. To detect an
effect size for MCST of 0.39 on the ADASCog with power
of 80% using a 5% significance level and an estimated
attrition of 15% needed, a sample size of 230 at T1 is
required. If an estimated 60 participants will have
Alzheimer's disease and are suitable/willing to take cho-
linesterase inhibitors (ACHEIs), this provides sufficient
numbers for the maintenance CST/ACHEIs trial plat-
form to estimate effect size and the feasibility of the trial.
Analyses
Statistical analyses of effectiveness
Analysis will be by intention to treat, in that all available
data will be included. Methods of imputation such as
LOCF (last observation carried forward) are of limited
utility in dementia, where the expectation is decline for
the usual treatment group, and participants will be lost
through death and illness. Hence our sample size calcula-
tions are based on the numbers estimated to be available
at the study end-point, 6 months after randomisation to
either the CST only group or the maintenance CST
group. Multi-level modelling will be used to address the
issue of clustering within randomised groups. We shall
also use analysis of covariance to adjust for baseline dif-
ferences in outcome variables [37]. Analyses will consider
the evaluation 6 months after the second randomisation
as the primary end-point. Secondary analyses will con-
sider the effects immediately following the CST, at 3 and
6 months. Age, gender, cholinesterase inhibitor and base-
line scores on the scales being examined will be entered
as covariates, together with 'centre' entered as a random
factor, because treatment has been defined as participa-
tion in the group programme within the confines of the
centres.
Economic evaluation
The primary economic evaluation is a cost-effectiveness
analysis. This study also offers an opportunity to conduct
a secondary cost-utility analysis. In addition, all costs and
effects for people with dementia will be set out in a cost-
consequence analysis. This analysis takes a public sector
perspective spanning the NHS (dementia services, pri-
mary and secondary care) and social care services funded
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received will be fully costed from the perspective of local
dementia services to generate a total programme cost and
cost per participant. We will estimate costs from data col-
lected in the validated Client Service Receipt Inventory
(CSRI), completed with the family care-giver or care
home manager. Costs will include those associated with
the CST and maintenance CST groups, primary and sec-
ondary health care services used by participants in the
intervention and control arms of the study (e.g. home/
surgery telephone contacts with GP and practice nurse,
outpatient and inpatient attendances at secondary care,
prescribing), home care, residential care placements, care
and support accessed through direct payments (or per-
sonal budgets), as well as indirect costs associated with
caregiver time and lost productivity.
Incremental Cost-effectiveness Analysis
The incremental cost-effectiveness ratio (ICER) measures
a ratio of costs to outcomes, with the denominator being
the difference in costs between the intervention and con-
trol groups, and the numerator being the difference
between these groups in an outcome measure. The pri-
mary analysis will compute the ICER for each of the pri-
mary outcomes in turn (ADAS-Cog, QOL-AD).
Secondary analyses will measure outcomes using utility
scores generated by the EQ5D and DEMQOL. Bootstrap
calculations, will be used for examining the uncertainty in
the cost-effectiveness analysis, to provide an estimate of
the probability distribution of the ICER, its confidence
interval, or variance in the ratio.
We will plot cost-effectiveness acceptability curves
(CEACs), which have been widely adopted as a method to
quantify and graphically represent uncertainty in eco-
nomic evaluation studies of health care technologies.
They can equally be used in the evaluation of public
health interventions. Sensitivity analysis will be under-
taken to test whether plausible changes in the values of
the main variables affect the results of the analysis.
Cost-consequence analysis is a variant of cost-effective-
ness analysis in which the components of incremental
costs and consequences (health outcomes) of alternative
programmes are listed without aggregation. This analysis
will be used for a comparison of secondary outcome mea-
sures of participants in the intervention and control arms
of the study. The inclusion of a cost-consequence analysis
in addition to the standard cost-effectiveness and cost-
utility analyses is to set out transparently the full range of
costs and consequences resulting from CST so as to assist
commissioners and policy makers responsible for funding
and coordinating services.
Discussion
This innovative and pragmatic RCT that evaluates the
effectiveness and cost-effectiveness of a maintenance
CST programme for dementia constitutes one of the larg-
est and longest trials for people with dementia and one of
the first including an integrated cost-effective analysis of
a psychosocial intervention. This study reflects the cur-
rent emphasis on improving cognition and quality of life
using psychosocial interventions, and the emphasis is on
working under a person-centred framework through
group exercises aiming at global stimulation of cognitive
abilities for a prolonged period of time. The NICE-SCIE
guidelines [8] on the management of dementia offer few
evidence-based recommendations about psychosocial
approaches. This is mainly due to the lack of high-quality
studies showing their efficacy and lack of specific guid-
ance for the duration that psychosocial interventions
should be provided. The results of this trial may therefore
contribute to future practice guidelines and, if successful,
will help the widespread use of psychosocial interven-
tions in dementia care such as CST within health and
social care services [38]. CST has now been evaluated in a
number of countries [21,39,40] and the UK National
Audit Office report highlighted that CST was available in
29% of community mental health teams for older people
[41].
This study should provide definitive evidence of the
potential efficacy of maintenance CST and establish how
far the long-term efficacy can be compared with antide-
mentia drugs such as cholinesterase inhibitors in terms of
cognition and quality of life. The results of this study,
both in terms of efficacy and cost-effectiveness, are likely
to influence the availability and provision of maintenance
CST in the UK and internationally, and will also impact
on evidence-based guidelines and strategic policies in
dementia care.
Appendix 1
Inclusion and exclusion criteria
Inclusion criteria
All participants are people with dementia who:
 meet the DSM-IV criteria for dementia of any type,
including Alzheimer's, vascular, Lewy Body type and
mixed
 are in the mild to moderate stage of dementia (Clinical
Dementia Rating)
 can communicate and understand communication in
English
 can engage in group activity for at least 45 minutes
Exclusion criteria
Participants do not have any characteristic which could
affect participation, e.g.: major physical illness; sensory
impairment; disability or high level of agitation.
Competing interests
AS runs the CST training course on a commercial basis.
AS, BW and MO have co-authored a CST manual, the royalties from which are
received by the Dementia Services Development Centre Wales.
Aguirre et al. Trials 2010, 11:46
http://www.trialsjournal.com/content/11/1/46
Page 9 of 10Authors' contributions
MO, RTW, ITR developed the original concept of the trial, and EA and MO
drafted the original protocol; ITR developed the design and methodology; MK
developed the health economic component; AS and JH co authored the treat-
ment manual; all authors reviewed and commented on drafts of the protocol
and paper.
Acknowledgements
Maintenance Cognitive Stimulation Programme (ISRCTN26286067) is part of 
the Support at Home - Interventions to Enhance Life in Dementia (SHIELD) 
project (Application No RP-PG-0606-1083) which is funded by the NIHR Pro-
gramme Grants for Applied research funding scheme. The grant holders are 
Professors Orrell (UCL), Woods (Bangor), Challis (Manchester), Moniz-Cook 
(Hull), Russell (Swansea), Knapp (LSE) and Dr Charlesworth (UCL).
The views and opinions expressed in this paper are those of the authors and 
do not necessarily reflect those of the Department of Health/NIHR.
Author Details
1Department of Mental Health Sciences, University College London, Charles 
Bell House, 67-73 Riding House Street, London, UK, 2Department of Clinical, 
Educational and Health Psychology, University College London, 1-19 
Torrington Place, London, UK, 3North Wales Organisation for Randomised Trials 
in Health and Social Care, Institute of Medical and Social Care Research, Bangor 
University, Ardudwy Hall, Normal Site, Holyhead Road, Bangor, UK, 4Centre for 
Economics of Mental Health, Institute of Psychiatry, London, UK and 
5Dementia Services Development Centre Wales, Institute of Medical and Social 
Care Research, Bangor University, Ardudwy Hall, Normal Site, Holyhead Road, 
Bangor, UK
References
1. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG: Systematic 
review of psychological approaches to the management of 
neuropsychiatric symptoms of dementia.  American Journal of Psychiatry 
2005, 162:1996-2021.
2. Woods RT: Non-pharmacological techniques.  In Evidence-based 
dementia practice Edited by: Qizilbash N. Oxford: Blackwell; 2002:428-446. 
3. Brodaty H, Green A, Koschera A: Meta-analysis of psychosocial 
interventions for caregivers of people with dementia.  JAGS 2003, 
51:657-664.
4. Clare L, Moniz-Cook E, Orrell M, Spector A, Woods B: Cognitive 
rehabilitation and cognitive training for early-stage Alzheimer's 
disease and vascular dementia.  In In The Cochrane Library Chichester: 
Wiley; 2004. 
5. Spector A, Orrell M, Davies S, Woods B: Reality orientation for dementia: 
a review of the evidence of effectiveness (Cochrane Review).  In In The 
Cochrane Library Oxford: Update Software; 1998. 
6. Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, 
Orrell M: A randomised controlled trial investigating the effectiveness 
of an evidence-based cognitive stimulation therapy programme for 
people with dementia.  British Journal of Psychiatry 2003, 183:248-254.
7. Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, Orrell M: 
Cognitive stimulation therapy for people with dementia: cost-
effectiveness analysis.  British Journal of Psychiatry 2006, 188:574-580.
8. National Institute for Health and Clinical Excellence and the Social Care 
Institute for Excellence (NICE-SCIE): Dementia: supporting people with 
dementia and their carers in health and social care. Clinical Guideline 
42.  London: NICE-SCIE; 2006. 
9. Orrell M, Spector A, Thorgrimsen L, Woods B: A pilot study examining the 
effectiveness of maintenance Cognitive Stimulation Therapy (MCST) 
for people with dementia.  International Journal of Geriatric Psychiatry 
2005, 20:446-451.
10. Olazaran J, Muniz R, Reisberg B, Peña-Casanova J, del Ser T, Cruz-Jentoft 
AJ, Serrano P, Navarro E, García de la Rocha ML, Frank A, Galiano M, 
Fernández-Bullido Y, Serra JA, González-Salvador MT, Sevilla C: Benefits of 
cognitive-motor intervention in MCI and mild to moderate Alzheimer's 
disease.  Neurology 2004, 63:2348-2353.
11. Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, 
Lambertucci P, Silveri MC, Bernabei R: Reality orientation therapy 
combined with cholinesterase inhibitors in Alzheimer's disease: 
randomised controlled trial.  British Journal of Psychiatry 2005, 
187:450-455.
12. Gerber GJ, Prince PN, Snider HG, Atchison K, Dubois L, Kilgour JA: Group 
activity and cognitive improvement among patients with Alzheimer's 
disease.  Hospital and Community Psychiatry 1991, 42(8):843-845.
13. Wallis GG, Baldwin M, Higginbotham P: Reality orientation therapy-a 
controlled trial.  British Journal of Medical Psychology 1983, 56(3):271-277.
14. Zanetti O, Frisoni GB, De Leo D, Buono MD, Bianchetti A, Trabucci M: 
Reality Orientation Therapy in Alzheimer's disease: Useful or not? A 
controlled study.  Alzheimer's disease and Associated Disorders 1995, 
9:132-138.
15. Metitieri T, Zanetti O, Geroldi C, Frisoni GB, De Leo D, Dello Buono M, 
Bianchetti A, Trabucchi M: Reality Orientation Therapy to delay 
outcomes of progression in patients with dementia: A retrospective 
study.  Clinical Rehabilitation 2001, 15:471-478.
16. Folstein MF, Folstein SE, McHugh PR: 'Mini Mental State': a practical 
method for grading the cognitive state of patients for the clinician.  
Journal of Psychiatric Research 1975, 12:189-198.
17. Ferrario E, Cappa G, Molaschi M, Rocco M, Fabris F: Reality orientation 
therapy in institutionalized elderly patients: Preliminary results.  
Archives of Gerontology and Geriatrics 1991, 12(2):139-42.
18. Woods RT: Reality Orientation and Staff attention: A Controlled Study.  
British Journal of Psychiatry 1979, 134:502-7.
19. Woods B, Spector A, Prendergast L, Orrell M: Cognitive stimulation to 
improve cognitive functioning in people with dementia.  Cochrane 
Database Syst Rev 2005, 4:CD005562.
20. Baines S, Saxby P, Ehlert K: Reality orientation and reminiscence therapy 
A controlled cross-over study of elderly confused people.  British 
Journal of Psychiatry 1987, 151:222-31.
21. Requena C, Maestu F, Campo P, Fernandez A, Ortiz T: Effects of 
cholinergic drugs and cognitive training on dementia: 2-year follow-
up.  Dementia and Geriatric Cognitive Disorders 2006, 22(4):339-345.
22. Aguirre E, Spector A, Streater A, Burnell K, Orrell M: Service users' 
involvement in the development of a maintenance Cognitive 
Stimulation Therapy (CST) programme: A comparison of the views of 
people with dementia, staff and family carers.  Dementia Journal  in 
press.
23. Gadner C: The impact of Cognitive Stimulation Therapy groups on 
people with dementia: views from participants, their carers and group 
facilitators.  In D Clin Psy Thesis University College London; 2009. 
24. Office of Public Sector Information (OPSI): Mental Capacity Act 2005 [http:/
/www.opsi.gov.uk/acts/acts2005/ukpga_20050009_en_1].
25. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's 
disease.  American Journal of Psychiatry 1984, 141:1356-64.
26. Logsdon RG, Gibbons LE, McCurry SM, Teri L: Assessing quality of life in 
older adults with cognitive impairment.  Psychosomatic Medicine 2002, 
64:510-519.
27. Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, de Vugt 
M, Mountain G, O'Connell M, Harrison J, Vasse E, Dröes RM, Orrell M: A 
European consensus on outcome measures for psychosocial 
intervention research in dementia care.  Aging & Mental Health 2008, 
12(1):14-25.
28. Holden UP, Woods RT: Positive Approaches to Dementia Care.  3rd 
edition. Edinburgh: Churchill Livingstone; 1995. 
29. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for 
Depression in Dementia.  Biological Psychiatry 1988, 23:271-284.
30. Shankar KK, Walker M, Frost D, Orrell MW: The development of a valid 
and reliable scale for rating anxiety in dementia (RAID).  Aging & Mental 
Health 1999, 3(1):39-49.
31. Cummings L, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, 
Gornbein J: The Neuropsychiatric Inventory: Comprehensive 
assessment of psychopathology in dementia.  Neurology 1994, 
44:2308-2314.
32. Galasko D, Bennet D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: 
An inventory to assess activities of daily living for clinical trials in 
Alzheimer's disease. The Alzheimer Disease Cooperative Study.  
Alzheimer Disease & Associated Disorders 1997, 11:S33-39.
33. Ware JE Jr, Kosinki M, Keller S: A 12 tem short form health survey. 
Construction of scales and preliminary tests of reliability and validity.  
Medical Care 1996, 34:220-223.
Received: 25 March 2010 Accepted: 28 April 2010 
Published: 28 April 2010
This article is available from: http://www.trialsjournal.com/content/11/1/46© 2010 Aguirre et l; licensee BioMed Centr l Ltd. is an Open Access articl d stributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.rials 2010, 11:46
Aguirre et al. Trials 2010, 11:46
http://www.trialsjournal.com/content/11/1/46
Page 10 of 1034. Beecham J, Knapp M: Costing psychiatric interventions.  In Measuring 
mental health needs Edited by: Thornicroft G, Brewin C, Wing J. London: 
Gaskell; 1992:163-183. 
35. EuroQoL Group: EuroQoL: A new facility for the measurement of health 
related quality of life.  Health Policy 1990, 16:199-208.
36. Smith SC, Lamping DL, Banerjee S, Harwood A, Foley B, Smith P, Cook JC, 
Murray J, Prince M, Levin E, Mann A, Knapp M: 'Measurement of health-
related quality of life for people with dementia: development of a new 
instrument (DEMQOL) and an evaluation of current methodology'.  
Health Technology Assessment 2005, 9(10):1-112.
37. Vickers AJ, Altman DG: Analysing controlled trials with baseline and 
follow up measurements.  British Medical Journal 2001, 323:1123-1124.
38. National Audit Office: Improving Services and support for people with 
dementia. Report by the comptroller and auditor general.  The 
Stationery office, London, UK; 2008. 
39. Matsuda O: Cognitive stimulation therapy for Alzheimer's disease: the 
effect of cognitive stimulation therapy on the progression of mild 
Alzheimer's disease in patients treated with donepezil.  International 
Psychogeriatrics 2007, 19(2):241-52.
40. Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J: Effects of 
cognitive-communication stimulation for Alzheimer's disease patients 
treated with donepezil.  Journal of Speech, Language, and Hearing 
Research 2004, 47(5):1149-63.
41. National Audit Office: Improving Services and support for people with 
dementia. Report by the comptroller and auditor general.  The 
Stationery office, London, UK; 2007. 
doi: 10.1186/1745-6215-11-46
Cite this article as: Aguirre et al., Maintenance Cognitive Stimulation Ther-
apy (CST) for dementia: A single-blind, multi-centre, randomized controlled 
trial of Maintenance CST vs. CST for dementia Trials 2010, 11:46
